| Value | ₹14,804 Cr |
|---|
NSE filing, NSE: DALBHARAT. Summary written from the filing by ALFA Finder's alert engine.
Dalmia Bharat Ltd: key numbers
- Share price
- ₹1,407.00
- Market cap
- ₹26,391 Cr
- Revenue (annual)
- ₹14,804 Cr
- Net profit (annual)
- ₹1,139 Cr
- P/E (TTM)
- 53.9×Sector 31.3×
- Promoter holding
- 55.84%+0.00% QoQ
- FII holding
- 7.41%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dalmia Bharat Ltd
All →Dalmia Bharat Earnings Call Transcript: Key Takeaways
Dalmia Bharat reported a weak Q2 with EBITDA/ton dropping to ₹698 due to East market floods and cost inflation. Despite volume growth, exceptional impairment charges for old thermal plants and brand transitions hurt the bottom line.
Dalmia Bharat Dividend
Dalmia Bharat Limited declared an interim dividend of Rs 4 per equity share at its 26-Oct-2026 board meeting. The record date for the dividend is 30-Oct-2026.
Dalmia Bharat Investor Presentation: Key Takeaways
Q2 FY27 revenue Rs 3,563 Cr (+4% YoY), EBITDA Rs 493 Cr (-29% YoY), reported PAT loss Rs 205 Cr after Rs 282 Cr impairment; volumes 7.1 MnT (+3% YoY).
Dalmia Bharat Results Update
Dalmia Bharat reported Q2 FY27 revenue of ₹3,563 Cr, PAT loss of ₹205 Cr. Trial run began at 3.6 MnTPA Belgaum clinker line, ahead of schedule.
- clinker trial run capacity
- 3.6 MnTPA
Dalmia Bharat Q2 FY27 Results: Net Loss of ₹205 Cr
Dalmia Bharat Ltd reported revenue from operations of ₹3,563 Cr (+4.3% YoY) and a net loss of ₹205 Cr for Q2 FY27.
- Key figure
- Net loss ₹205 Cr
Dalmia Bharat Annual General Meeting
Dalmia Bharat Limited declared voting results of its Postal Ballot, where shareholders approved the remuneration for its Managing Directors.
Other results update announcements
All →Indostar Capital Finance Results Update
IndoStar reported Q2 FY27 standalone results, with disbursements up 51% YoY to ₹1,399 crore. Profit after tax rose to ₹13.1 crore and AUM reached ₹8,459 crore.
Alivus Life Sciences Results Update
Alivus Life Sciences reported Q2FY27 revenue of Rs. 6,820 Mn (up 16.0% YoY) and PAT of Rs. 1,968 Mn in a press release. Investors see record EBITDA margins of 41.8% and capex progress at Solapur and Taloja.
Asset Reconstruction Company (India) Results Update
ARCIL's H1FY27 release shows total income up 48% to Rs.516.4 crore and PAT up 54% to Rs.290.0 crore. Investors should view performance over a longer horizon.
Capital Small Finance Bank Results Update
Capital SFB's Q2 FY27 PAT rose 30.7% year-on-year to ₹45.61 crore, while advances grew 23.4%. Asset quality improved, with GNPA at 2.36% and NNPA at 1.12%.
Strides Pharma Science Results Update
Strides Pharma reported Q2FY27 revenue of ₹14,297m, up 17.1% YoY, and EBITDA of ₹2,509m, up 8.4%, in a press release. Reported PAT rose 2.0% to ₹1,341m.
Fiberweb (India) Results Update
Fiberweb India's Q2 FY27 press release shows total income of ₹30.99 crore, up 209.36% quarter-on-quarter. Net profit rose to ₹1.27 crore.